What is it about?
Looks at the problem of a pharmaceutical company deciding which drugs to develop faced with a number of projects that may have different stages of maturity. The devil is in the detail and the cost probability architecture of projects is essential to establishing their value. Suggests that the Pearson Index is a useful tool for evaluating projects but others that have been promoted are misleading.
Featured Image
Why is it important?
Makes the issues clear using simple examples with a minimal resort to algebra but establishes nonetheless some useful general results and principles
Read the Original
This page is a summary of: SOME STATISTICAL ISSUES IN PROJECT PRIORITIZATION IN THE PHARMACEUTICAL INDUSTRY, Statistics in Medicine, December 1996, Wiley,
DOI: 10.1002/(sici)1097-0258(19961230)15:243.0.co;2-k.
You can read the full text:
Resources
Contributors
The following have contributed to this page
